Prof Alberto Briganti speaks to ecancer about the PROTEUS substudy, which evaluated perioperative apalutamide plus androgen deprivation therapy (ADT) alongside radical prostatectomy and pelvic lymph node dissection in patients with high risk localised or locally advanced prostate cancer. Compared with surgery alone, perioperative apalutamide plus ADT significantly improved event free survival, reducing the risk of recurrence or death by 62%.
Dena Battle
As seen in:
MDPI,
U.S. News and World Report,
STAT,
eCancer,
European Urology,
European Urology Focus,
UroToday
Kidney cancer advocate involved in Patient 2.0 and Health 2.0 communities.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Dena
Contact Dena, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack